Anton Simeonov
Anton Simeonov is the Scientific Director in the Division of Pre-Clinical Innovation, at the National Center for Advancing Translational Sciences (NCATS) - National Institutes of Health. The author or inventor on more than 140 peer-reviewed scientific publications and patents, Simeonov has a truly diverse background, ranging from bioorganic chemistry and molecular biology to clinical diagnostic research and development. He received a Ph.D. in bioorganic chemistry from the University of Southern California and a B.A. in chemistry from Concordia College. Simeonov then trained as a postdoctoral fellow at the Scripps Research Institute under Richard Lerner, M.D., and Kim Janda, Ph.D.
Prior to joining NIH in November 2004, Simeonov was a senior scientist at Caliper Life Sciences, a leading developer of microfluidic technologies, where he was responsible for basic research on novel assay methodologies and development of microfluidic products for research and clinical diagnostics. Simeonov is a literature editor of Assay and Drug Development Technologies and a member of the editorial board of Expert Opinion on Drug Discovery and Drug Target Review.
Contact Information: anton.simeonov@nih.gov; 301-594-8966
Anton Simeonov is the Scientific Director in the Division of Pre-Clinical Innovation, at the National Center for Advancing Translational Sciences (NCATS) - National Institutes of Health. The author or inventor on more than 140 peer-reviewed scientific publications and patents, Simeonov has a truly diverse background, ranging from bioorganic chemistry and molecular biology to clinical diagnostic research and development. He received a Ph.D. in bioorganic chemistry from the University of Southern California and a B.A. in chemistry from Concordia College. Simeonov then trained as a postdoctoral fellow at the Scripps Research Institute under Richard Lerner, M.D., and Kim Janda, Ph.D.
Prior to joining NIH in November 2004, Simeonov was a senior scientist at Caliper Life Sciences, a leading developer of microfluidic technologies, where he was responsible for basic research on novel assay methodologies and development of microfluidic products for research and clinical diagnostics. Simeonov is a literature editor of Assay and Drug Development Technologies and a member of the editorial board of Expert Opinion on Drug Discovery and Drug Target Review.
Contact Information: anton.simeonov@nih.gov; 301-594-8966
